Regenxbio (RGNX) Other Non-Current Liabilities (2018 - 2025)

Regenxbio's Other Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $638000.0 for Q4 2025.

• On a quarterly basis, Other Non-Current Liabilities fell 82.45% year-over-year to $638000.0 in Q4 2025; TTM through Dec 2025 was $638000.0, a 82.45% decrease from a year earlier, with the FY2025 full-year figure at $638000.0, down 82.45% from the prior year.
• Other Non-Current Liabilities declined to $638000.0 in Q4 2025 per RGNX's latest filing, from $648000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $171.3 million in Q4 2021 and bottomed at $448000.0 in Q1 2021.
• The 5-year median for Other Non-Current Liabilities is $6.9 million (2022), against an average of $37.5 million.
• Across the five-year window, Other Non-Current Liabilities surged 26379.82% in 2021 and plunged 98.15% in 2025, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $171.3 million in 2021, then dropped by 19.69% to $137.6 million in 2022, then tumbled by 68.4% to $43.5 million in 2023, then sank by 91.64% to $3.6 million in 2024, then tumbled by 82.45% to $638000.0 in 2025.
• Per Business Quant, the three latest RGNX Other Non-Current Liabilities figures stand at $638000.0 (Q4 2025), $648000.0 (Q3 2025), and $664000.0 (Q2 2025).